統計學系

Medicine & Life Sciences

1. Neoplasms 98%
2. Survival 66%
3. Non-Small Cell Lung Carcinoma 56%
4. Genes 53%
5. Datasets 53%
6. Sample Size 49%
7. Clinical Trials 43%
8. Therapeutics 43%
9. Biomarkers 41%
10. Lung Neoplasms 40%
11. Single Nucleotide Polymorphism 37%
12. Proteomics 37%
13. Rheumatoid Arthritis 35%
14. Diffuse Scleroderma 34%
15. Mutation 33%
16. Data Analysis 32%
17. Statistics 31%
18. Proteins 31%
19. Gene Expression 31%
20. High-Throughput Nucleotide Sequencing 30%
21. Paclitaxel 30%
22. Population 30%
23. Radiotherapy 29%
24. Colorectal Neoplasms 28%
25. Exome 28%
26. Drug Therapy 27%
27. Genome 27%
28. Lung 26%
29. Logistic Models 26%
30. Hepatocellular Carcinoma 26%
31. Cohort Studies 26%
32. Adenocarcinoma 26%
33. Confidence Intervals 24%
34. Randomized Controlled Trials 23%
35. Transcriptome 23%
36. Mortality 22%
37. Carcinoma 22%
38. Haplotypes 21%
39. Pharmaceutical Preparations 21%
40. Linear Models 21%
41. Odds Ratio 21%
42. RNA-Seq 21%
43. Triple Negative Breast Neoplasms 20%
44. ErbB Receptors 20%
45. Carcinogenesis 20%
46. Growth 19%
47. Systemic Scleroderma 19%
48. Costs and Cost Analysis 19%
49. Urinary Bladder Neoplasms 19%
50. Transitional Cell Carcinoma 18%
51. Renal Dialysis 18%
52. Quality Control 18%
53. Rheumatology 18%
54. Genotype 18%
55. Penicillamine 18%
56. Mass Spectrometry 17%
57. Transforming Growth Factors 17%
58. Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry 17%
59. Head and Neck Neoplasms 17%
60. Thorax 17%
61. Skin 16%
62. Joints 16%
63. Polyps 16%
64. Polycyclic Aromatic Hydrocarbons 16%
65. MicroRNAs 16%
66. Adenoma 16%
67. Tomography 16%
68. Technology 16%
69. Nonlinear Dynamics 15%
70. Machine Learning 15%
71. Phenotype 15%
72. Statistical Models 15%
73. Schizophrenia 15%
74. Cluster Analysis 15%
75. RNA 15%
76. Quality of Life 15%
77. Hospitalization 15%
78. Atlases 14%
79. Research Personnel 14%
80. Small Cell Lung Carcinoma 14%
81. Meta-Analysis 14%
82. Research Design 13%
83. Cell Line 13%
84. Serum 13%
85. Longitudinal Studies 13%
86. Health 13%
87. Kidney 13%
88. Prospective Studies 13%
89. Squamous Cell Carcinoma 12%

Mathematics

1. Design 100%
2. Model 50%
3. Clinical Trials 48%
4. D-optimal Design 42%
5. Longitudinal Data 42%
6. Linear Mixed Model 34%
7. Simulation Study 33%
8. Multiple Objectives 31%
9. Gene 31%
10. Experiment 29%
11. Drugs 29%
12. Performance 28%
13. Sample Size 28%
14. Right-censored Data 27%
15. Missing Values 26%
16. Dose-response 26%
17. Testing 25%
18. Regression Model 25%
19. Methodology 24%
20. Polynomial Model 24%
21. Metaheuristics 23%
22. Two-stage Design 21%
23. Mediation 21%
24. Heteroscedasticity 21%
25. Minimax 21%
26. Evaluate 20%
27. Nonlinear Mixed Effects Model 20%
28. Sample Size Calculation 19%
29. Estimator 19%
30. Mediator 19%
31. Bayesian Optimal Design 19%
32. Conditional Expectation 19%
33. Demonstrate 19%
34. Sequencing 18%
35. Heteroscedastic Model 18%
36. Modeling 18%
37. Bayesian Design 18%
38. Random Effects 17%
39. Nonlinear Model 17%
40. Regression 17%
41. Model-based Clustering 16%
42. Efficacy 16%
43. Observation 16%
44. Simulation 16%
45. Toxicity 15%
46. Skew 15%
47. Gene Expression 14%
48. Cancer 14%
49. Maximum Likelihood Estimation 14%
50. Multiple Comparisons 14%
51. Binary Response 14%
52. Proportion 14%
53. Strategy 14%
54. Adaptive Design 14%
55. Scleroderma 14%
56. Estimate 13%
57. Genome 13%
58. Logistic Model 13%
59. Prediction 13%
60. Poisson Model 13%
61. Randomized Trial 13%
62. Equivalence Theorem 13%
63. Cell 12%
64. t-distribution 12%
65. Relationships 12%
66. Confidence interval 12%
67. Robustness 12%
68. Model Discrimination 12%
69. Clustered Data 12%
70. Kaplan-Meier 12%
71. Sample Size Determination 12%
72. Paired Data 12%
73. Linear Model 12%
74. Randomisation 12%
75. Control Charts 12%
76. Clustering 12%
77. Missing at Random 11%
78. Poisson Regression 11%
79. Parameter Estimation 11%
80. Bayesian Analysis 11%
81. Genomics 11%
82. Locally Optimal Design 11%
83. Linear Mixed Effects Model 11%
84. Statistics 11%
85. Dose Finding 11%
86. Causal Effect 11%
87. Unknown 11%
88. Multivariate Data 11%
89. Adaptive Sampling 11%